Clinical Significance of Adjuvant Therapy After Radical Surgery for Primary Osteosarcoma of the Jaws

Overview

Journal Wien Klin Wochenschr

Publisher Springer

Specialty General Medicine

Date 2023 Jun 12

PMID 37308792

Authors

Shenghong Wu

Yu Wang

Jinfeng Zhang

Zhonghui He

Yuanjue Sun

Ming Ye

Affiliations

Soon will be listed here.

Abstract

Background: Osteosarcoma of the jaw is one of the rare malignancies and the role of postoperative adjuvant therapy is unclear. This study explored the efficacy of adjuvant therapy after radical surgery for primary osteosarcoma of the jaw.

Methods: The data were retrospectively analyzed from May 2012 to June 2021. The recurrence rate, disease-free survival (DFS) and 5‑year overall survival (OS) rate were calculated by Kaplan-Meier method. Intergroup rates were examined by chi-square test.

Results: 125 post-radical surgery patients were included. The median follow-up time was 66 months. Forty five cases suffered recurrence. The recurrence rate was 36.0%, and the 5‑year OS rate was 68.8%. In the adjuvant treatment group, twenty eight of 99 patients experienced disease progression. In the surgical treatment alone group, seventeen of 26 patients experienced disease progression. The recurrence rates in the two groups were 28.3 and 65.4%, respectively (χ = 12.303, p < 0.001). The 5‑year OS rate was 75.8 and 42.3%, respectively (χ = 10.734, p = 0.001). The median DFS of the relapse patients was 15.1 months (95% CI:13.00-17.20 months), and the 5‑year OS rate was 40.0%. Among them, 28 patients received adjuvant therapy while 17 received surgical treatment alone. The median DFS was 15.7 and 11.5 months, respectively, p = 0.024. The median OS was 69.6 months (95% CI 55.69 ~ 83.51 months) and 62.4 months (95% CI 49.06 ~ 75.74 months), respectively(p = 0.034).

Conclusion: Adjuvant therapy is one of the effective measures to reduce the relapse rate and improve OS after radical surgery for primary osteosarcoma of the jaw.

References

Choi J, Ro J . The 2020 WHO Classification of Tumors of Bone: An Updated Review. Adv Anat Pathol. 2021; 28(3):119-138. DOI: 10.1097/PAP.0000000000000293. View

Clark J, Unni K, Dahlin D, DEVINE K . Osteosarcoma of the jaw. Cancer. 1983; 51(12):2311-6. DOI: 10.1002/1097-0142(19830615)51:12<2311::aid-cncr2820511224>3.0.co;2-z. View

Granowski-LeCornu M, Chuang S, Kaban L, August M . Osteosarcoma of the jaws: factors influencing prognosis. J Oral Maxillofac Surg. 2011; 69(9):2368-75. DOI: 10.1016/j.joms.2010.10.023. View

Bennett J, Thomas G, Evans A, Speight P . Osteosarcoma of the jaws: a 30-year retrospective review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 90(3):323-32. DOI: 10.1067/moe.2000.108274. View

Mardinger O, Givol N, Talmi Y, Taicher S . Osteosarcoma of the jaw. The Chaim Sheba Medical Center experience. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 91(4):445-51. DOI: 10.1067/moe.2001.112330. View

Smith R, Apostolakis L, Karnell L, Koch B, Robinson R, Zhen W . National Cancer Data Base report on osteosarcoma of the head and neck. Cancer. 2003; 98(8):1670-80. DOI: 10.1002/cncr.11716. View

Kontio R, Hagstrom J, Lindholm P, Bohling T, Sampo M, Mesimaki K . Craniomaxillofacial osteosarcoma - The role of surgical margins. J Craniomaxillofac Surg. 2019; 47(6):922-925. DOI: 10.1016/j.jcms.2019.03.020. View

Ricotta F, Bassi M, Tomasetti N, Campobassi A, Maiolo V, Bertoni F . Osteosarcoma of the Jaws: A Literature Review. Curr Med Imaging. 2020; 17(2):225-235. DOI: 10.2174/1573405616666200806173948. View

Patel S, Meyers P, Huvos A, Wolden S, Singh B, Shaha A . Improved outcomes in patients with osteogenic sarcoma of the head and neck. Cancer. 2002; 95(7):1495-503. DOI: 10.1002/cncr.10849. View

10.

van Es R, Keus R, van der Waal I, Koole R, Vermey A . Osteosarcoma of the jaw bones. Long-term follow up of 48 cases. Int J Oral Maxillofac Surg. 1997; 26(3):191-7. DOI: 10.1016/s0901-5027(97)80818-1. View

11.

Kammerer P, Shabazfar N, Vorkhshori Makoie N, Moergel M, Al-Nawas B . Clinical, therapeutic and prognostic features of osteosarcoma of the jaws - experience of 36 cases. J Craniomaxillofac Surg. 2011; 40(6):541-8. DOI: 10.1016/j.jcms.2011.10.001. View

12.

Chindia M . Osteosarcoma of the jaw bones. Oral Oncol. 2001; 37(7):545-7. DOI: 10.1016/s1368-8375(00)00129-9. View

13.

Eder-Czembirek C, Moser D, Holawe S, Brodowicz T, Ries J, Sulzbacher I . Osteosarcoma of the jaw - experience at the Medical University Vienna and comparative study with international tumor registries. Clinics (Sao Paulo). 2019; 74:e701. PMC: 6467170. DOI: 10.6061/clinics/2019/e701. View

14.

Bertin H, Gomez-Brouchet A, Redini F . Osteosarcoma of the jaws: An overview of the pathophysiological mechanisms. Crit Rev Oncol Hematol. 2020; 156:103126. DOI: 10.1016/j.critrevonc.2020.103126. View

15.

Slootweg P, Muller H . Osteosarcoma of the jaw bones. Analysis of 18 cases. J Maxillofac Surg. 1985; 13(4):158-66. DOI: 10.1016/s0301-0503(85)80040-0. View

16.

Delgado R, Maafs E, Alfeiran A, Mohar A, Barrera J, Zinser J . Osteosarcoma of the jaw. Head Neck. 1994; 16(3):246-52. DOI: 10.1002/hed.2880160307. View

17.

Lee R, Arshi A, Schwartz H, Christensen R . Characteristics and prognostic factors of osteosarcoma of the jaws: a retrospective cohort study. JAMA Otolaryngol Head Neck Surg. 2015; 141(5):470-7. DOI: 10.1001/jamaoto.2015.0340. View

18.

Laskar S, Basu A, Muckaden M, DCruz A, Pai S, Jambhekar N . Osteosarcoma of the head and neck region: lessons learned from a single-institution experience of 50 patients. Head Neck. 2008; 30(8):1020-6. DOI: 10.1002/hed.20820. View

19.

Ferrari D, Codeca C, Battisti N, Broggio F, Crepaldi F, Violati M . Multimodality treatment of osteosarcoma of the jaw: a single institution experience. Med Oncol. 2014; 31(9):171. DOI: 10.1007/s12032-014-0171-9. View

20.

Thariat J, Julieron M, Brouchet A, Italiano A, Schouman T, Marcy P . Osteosarcomas of the mandible: are they different from other tumor sites?. Crit Rev Oncol Hematol. 2011; 82(3):280-95. DOI: 10.1016/j.critrevonc.2011.07.001. View